Associated Papers
Assessment of pathogenic variation in gynecologic cancer genes in a national cohort.
Kotnik U et al.
Scientific Reports, 2023
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
Dorling L et al.
The New England Journal of Medicine, 2021
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Yadav S et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2020
rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.
Liu J et al.
Scientific Reports, 2016
27845421 (PubMed )
Supplement: srep36874-s1.pdf
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E et al.
Journal of Medical Genetics, 2012
Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
De Brakeleer S et al.
Human Mutation, 2010
Hereditary breast cancer: new genetic developments, new therapeutic avenues.
Campeau PM et al.
Human Genetics, 2008
The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN et al.
Plos Medicine, 2006
Select a paper to view details